Efficacy of Vestibular Rehabilitation Therapy on Benign Paroxysmal Positional Vertigo After Repositioning: Improvement of Vestibular Symptoms and Vertigo Disability
Listen to this summary
The authors aimed to evaluate the efficacy of vestibular rehabilitation therapy (VRT) for patients with benign paroxysmal positional vertigo (BPPV) who continue to experience symptoms after repositioning, and to explore differences between the two subtypes of BPPV: posterior canal (pc-BPPV) and horizontal canal (hc-BPPV). The study found that VRT significantly improved residual symptoms compared to a control group, with subtype-specific differences observed in early symptom relief and functional recovery. These findings suggest that VRT can enhance rehabilitation outcomes for BPPV patients, highlighting the importance of tailored approaches based on BPPV subtype.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
View all →Jun 11, 2026 · Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
Early Identification and Management of Otogenic and Nonotogenic Cerebral Venous Sinus Thrombosis
Jun 11, 2026 · Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
Medical Therapy for NF2-related Schwannomatosis: A Systematic Review of Current Evidence
More in Otolaryngology
View all →Jun 24, 2026 · The New England journal of medicine
A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
Jun 24, 2026 · The New England journal of medicine
Prevention and Treatment of Peanut Allergy
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
Jun 24, 2026 · The New England journal of medicine
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
Jun 24, 2026 · JAMA
Self-Directed vs Clinician-Delivered Cognitive Behavioral Therapy for Chronic Pain: A Randomized Clinical Trial
Jun 24, 2026 · Lancet (London, England)
Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


